KALA BIO, Inc. (KALA): who owns it and who trades it
As of Nov 12, 2026, no open-market insider purchases or sales of KALA were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No KALA insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KALA short interest
Low short interest. 2.0% of KALA shares are sold short: about 1 share in 51. Over the last 12 reports the number of shares short went up 799%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 382,804 KALA shares were sold short, 2.0% of the shares outstanding, down 29.0% from the report before. At the average daily volume of 211,044 shares, buying them all back would take about 1.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 382,804 | 1.98% | -29% | 211,044 | 1.8 |
| Oct 15, 2026 | 539,414 | 2.79% | -60% | 808,459 | 1.0 |
| Sep 30, 2026 | 1.36M | 7.03% | +205% | 6.22M | 1.0 |
| Sep 15, 2026 | 445,421 | 2.30% | +10% | 1.15M | 1.0 |
| Aug 31, 2026 | 403,121 | 2.08% | +58% | 286,651 | 1.4 |
| Aug 14, 2026 | 255,232 | 1.32% | -9% | 71,127 | 3.6 |
| Jul 31, 2026 | 279,430 | 0.03% | +9% | 117,662 | 2.4 |
| Jul 15, 2026 | 256,622 | 0.03% | +17% | 220,063 | 1.2 |
| Jun 30, 2026 | 218,549 | 0.02% | +237% | 213,635 | 1.0 |
| Jun 15, 2026 | 64,883 | 0.01% | -8% | 112,939 | 1.0 |
| May 29, 2026 | 70,709 | 0.01% | +66% | 69,148 | 1.0 |
| May 15, 2026 | 42,592 | 0.00% | -96% | 90,516 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
KALA Bio company events
KALA Bio filed 20 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership, listing, control). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Nov 3, 2026VoteReported shareholder vote results. Filing
- Sep 10, 2026AgreementKALA BIO, Inc. entered into an Exclusive Distribution and Reseller Agreement with Virotek, Inc., a Wyoming corporation. Filing
- Sep 9, 2026AnnouncementOf this Current Report on Form 8-K is incorporated by reference into this Item 5.08. Filing
- Aug 28, 2026ListingKALA BIO, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the Staff has determined that the closing bid price of the Company’s common stock, par value $0.001 per share, has been below $1.00 per share for the previous 30… Filing
- Jul 23, 2026AnnouncementThe Company filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act of 1933, as amended, relating to the offering of securities pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-295667). Filing
- May 7, 2026AnnouncementThe Company issued a press release announcing the Reverse Stock Split. Filing
- Mar 4, 2026AgreementKALA BIO, Inc. and 2624465 Ontario Inc. o/a Younet AI, an Ontario corporation entered into a Platform Development and Exclusive License Agreement pursuant to which the Company obtained a worldwide exclusive license of Younet’s proprietary, custom biomedical artificial intelligence research… Filing
- Feb 20, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Feb 5, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Feb 2, 2026ControlChanges in Control of the Registrant. Filing
- Jan 23, 2026ListingKALA Bio, Inc. received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between December 3, 2025, to January 16, 2026, the Company did not meet the… Filing
- Jan 8, 2026AgreementKALA BIO, Inc., entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC providing for the sale and issuance by the Company of shares of its common stock, par value $0.001 per share from time to time, through or to Wainwright as the Company’s sales agent or principal in an… Filing
- Jan 6, 2026AgreementKALA BIO, Inc. entered into a settlement agreement with Baker Bros. Filing
- Jan 2, 2026AnnouncementAs previously disclosed in the Kala Bio, Inc. Current Report on Form 8-K filed on November 25, 2025, the Company entered into a Loan Settlement Agreement with Oxford Finance, LLC pursuant to which the Company owed Oxford $2 million to be paid pursuant to the terms of the Settlement Agreement. Filing
- Dec 29, 2025AuditorChanges in Registrant’s Certifying Accountant As previously disclosed in the Company’s Current Report on Form 8-K filed on December 16, 2025, the audit committee of the Company’s Board of Directors approved the dismissal of Deloitte & Touche LLP as the Company’s independent registered public… Filing
- Dec 16, 2025AuditorThe Audit Committee of the Board of Directors of KALA BIO, Inc. approved the dismissal of Deloitte & Touche LLP as the Company’s independent registered public accounting firm, effective as of December 15, 2025. Filing
- Dec 16, 2025AnnouncementOf this Current Report on Form 8-K “Notice of Annual Meeting” is incorporated by reference into this Item 5.08. Filing
- Dec 5, 2025AgreementKALA BIO, Inc. entered into a securities purchase agreement with a certain institutional investor, pursuant to which the Company agreed to issue and sell in a registered direct offering (i) 900,000 shares of the Company’s common stock, par value $0.001 per share and (ii) pre-funded warrants to… Filing
- Nov 25, 2025LeadershipThe Board terminated without cause the employment of Mary Reumuth, the Company’s Chief Financial Officer and Secretary, effective as of the business day following the First Closing. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
KALA Bio financials
Famous investors that hold KALA
1 of the 50 well-known investors we track reported holding KALA in their latest 13F filing. The largest position is Jim Simons's, worth $34.8K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 81,100 | $34.8K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KALA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 19, 2026 | Labkowski Nachum | 13G | 5.0% |
| Oct 19, 2026 | Labkowski Nachum | 13G | 5.0% |
Questions about KALA BIO, Inc. (KALA) stock
Are KALA insiders buying or selling?
No KALA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in KALA?
As of Oct 30, 2026, 382,804 KALA shares were sold short, 2.0% of the shares outstanding, down 29.0% from the report before. At the average daily volume of 211,044 shares, buying them all back would take about 1.8 trading days (days to cover). See the history.
Which famous investors hold KALA?
1 of the 50 well-known investors we track reported KALA in their latest 13F filing, including Jim Simons. The largest position is worth $34.8K. See all holders.
Executive pay
KALA Bio's chief executive was paid a total of $907K for the year ended Dec 31, 2025, down 39% from $1.5M the year before. In the last 12 months, KALA Bio's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.